AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
India · Delayed Price · Currency is INR 7,827.50
-24.50 (-0.31%)
Apr 2, 2026, 3:29 PM IST
AstraZeneca Pharma India Employees
AstraZeneca Pharma India had 600 employees as of December 31, 2025. The number of employees decreased by 20 or -3.23% compared to the same quarter last year.
Employees
600
Change
-20
Growth
-3.23%
Revenue / Employee
36.29M INR
Profits / Employee
3.35M INR
Market Cap
195.44B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 600 | -20 | -3.23% |
| Sep 30, 2025 | 600 | -200 | -25.00% |
| Jun 30, 2025 | 600 | -300 | -33.33% |
| Mar 31, 2025 | 802 | -138 | -14.68% |
| Dec 31, 2024 | 620 | -320 | -34.04% |
| Sep 30, 2024 | 800 | - | - |
| Jun 30, 2024 | 900 | -47 | -4.96% |
| Mar 31, 2024 | 940 | -7 | -0.74% |
| Mar 31, 2023 | 947 | -236 | -19.95% |
| Mar 31, 2022 | 1,183 | -100 | -7.79% |
| Mar 31, 2021 | 1,283 | -42 | -3.17% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ipca Laboratories | 16,778 |
| Alembic Pharmaceuticals | 16,571 |
| Ajanta Pharma | 9,628 |
| Emcure Pharmaceuticals | 6,731 |
| Piramal Pharma | 5,476 |
| Gland Pharma | 4,351 |
| NATCO Pharma | 4,199 |
| Eris Lifesciences | 3,354 |
AstraZeneca Pharma India News
- 3 days ago - AstraZeneca Pharma India appoints Dr. Shashank Srinivasan and promotes Mr. Venkat Natarajan - Business Upturn
- 14 days ago - AstraZeneca Pharma India announces resignation of non-executive director Jesús Diaz-Ropero Esteso - Business Upturn
- 17 days ago - AstraZeneca Pharma India receives approval to market Imfinzi for unresectable hepatocellular carcinoma - Business Upturn
- 7 weeks ago - ASTRAZEN shares fall over 4% as Q3 EBITDA drops 41.8% YoY to Rs 44.8 crore - Business Upturn
- 7 weeks ago - Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment - NDTV
- 3 months ago - AstraZeneca Pharma India receives CDSCO approval to import and market Datverzo in India - Business Upturn
- 4 months ago - AstraZeneca Pharma India jumps 3% after teaming up with Sun Pharma to boost access to Hyperkalaemia treatment in India - Business Upturn
- 4 months ago - AstraZeneca and Sun Pharma partner to boost access to Hyperkalaemia treatment in India - Business Upturn